Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cardiovascular Systems's Enterprise Value is $733.2 Mil.
Cardiovascular Systems's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was $-36.1 Mil. Therefore, Cardiovascular Systems's EV-to-EBIT ratio for today is -20.31.
Cardiovascular Systems Enterprise Value Historical Data
The historical data trend for Cardiovascular Systems's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cardiovascular Systems's Enterprise Value
For the Medical Devices subindustry, Cardiovascular Systems's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiovascular Systems's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cardiovascular Systems's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Cardiovascular Systems's Enterprise Value falls into.
Cardiovascular Systems Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Cardiovascular Systems's Enterprise Value for the fiscal year that ended in Jun. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiovascular Systems (NAS:CSII) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Cardiovascular Systems's current Enterprise Value is $733.2 Mil.
Cardiovascular Systems's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.1 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Cardiovascular Systems's EV-to-EBITDA for today is:
Cardiovascular Systems's current Enterprise Value is $733.2 Mil.
Cardiovascular Systems's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.1 Mil.
Cardiovascular Systems's current Enterprise Value is $733.2 Mil.
Cardiovascular Systems's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $239.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiovascular Systems Enterprise Value Related Terms
Thank you for viewing the detailed overview of Cardiovascular Systems's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Cardiovascular Systems (Cardiovascular Systems) Business Description
Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generate the vast majority of its revenue in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CSII has been successfully added to your 